Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Chief Financial Officer | August 03, 2026 | August 04, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | CFO | February 23, 2023 | February 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,295 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 4,696 · Balance 96,295 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Vir Biotechnology, Inc.
Report date February 23, 2023 · Filed February 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 230,712 |
Reported balance
After 2023-02-23 transaction · row 1
1 source rowRow 1 · 2023-02-23 · Sale · Disposed 2,248 · Balance 230,712 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 4, 2026 19:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,696 | $24.92 | $117,024.32 |
DisclosureSEC source: 0001193125-26-332536 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,295 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 19:37 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,698 | $33.13 | $155,644.74 |
DisclosureSEC source: 0001193125-26-296128 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,991 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,653 | $23.77 | $110,601.81 |
DisclosureSEC source: 0001786335-26-000002 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,689 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:35 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,683 | $24.90 | $116,606.70 |
DisclosureSEC source: 0001193125-26-204402 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,342 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 59,952 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164247 · ownership.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,952 Underlying: Common Stock · 59,952 shares Expires 2036-04-16 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 34,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164247 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,025 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:19 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,683 | $20.97 | $98,202.51 |
DisclosureSEC source: 0001193125-26-140702 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,351 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,635 | $22.40 | $36,624.00 |
DisclosureSEC source: 0001193125-26-089107 · ownership.xml · nonDerivative · entry 4 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,034 F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,119 | $22.54 | $70,302.26 |
DisclosureSEC source: 0001193125-26-089107 · ownership.xml · nonDerivative · entry 3 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,669 Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 5,290 | $22.80 | $120,612.00 |
DisclosureSEC source: 0001193125-26-089107 · ownership.xml · nonDerivative · entry 2 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,788 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 6,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089107 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,078 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,061 | $23.56 | $72,117.16 |
DisclosureSEC source: 0001193125-26-034832 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,935 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,150 | $22.84 | $71,946.00 |
DisclosureSEC source: 0001193125-26-002410 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,996 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 17:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,081 | $36.38 | $112,086.78 |
DisclosureSEC source: 0001193125-25-315460 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,146 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 16:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,942 | $31.51 | $250,252.42 |
DisclosureSEC source: 0001193125-25-238708 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,227 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 16:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,785 | $40.40 | $72,114.00 |
DisclosureSEC source: 0000950170-25-036056 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,169 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.73 to $41.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 28,160 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032750 · ownership.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,160 Underlying: Common Stock · 28,160 shares Expires 2035-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 15,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032750 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,954 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 10, 2024 Filed Oct 11, 2024 20:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,465 | $52.76 | $393,853.40 |
DisclosureSEC source: 0000950170-24-114378 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,301 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 34,200 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026672 · ownership.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires 2034-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 19,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026672 · ownership.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,766 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. The amount of securities beneficially owned in column 5 reflects the correction of a typographical error in the Form 4 filed by the Reporting Person on October 10, 2023 (the "October 2023 Form 4"). The accurate number of securities beneficially owned by the Reporting Person in Column 5 of the October 2023 Form 4 is 80,366. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 16:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 140,469 | $0.00 Strike: $35.68 | $0.00 |
DisclosureSEC source: 0001209191-23-052466 · doc4.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,469 Underlying: Common Stock · 140,469 shares Expires 2033-10-09 F2 · derivative.exercise_date: The option shall vest with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares initially subject to the option shall continue to vest on each month such that the option will fully vest on the fourth anniversary of the grant date. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 16:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 80,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052466 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,336 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's Employment Inducement Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,248 | $25.97 | $58,387.30 |
DisclosureSEC source: 0001209191-23-013007 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,712 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,424 | $25.29 | $61,298.11 |
DisclosureSEC source: 0001209191-23-011382 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,960 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-012951 · doc4.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012951 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,384 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,393 | $31.93 | $76,410.64 |
DisclosureSEC source: 0001209191-22-011735 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,384 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $67.38 | $0.00 |
DisclosureSEC source: 0001209191-21-011920 · doc4.xml · derivative · entry 2 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011920 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,777 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 30,000 | $50.06 | $1,501,731.00 |
DisclosureSEC source: 0001209191-20-042489 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-20-040660 · doc4.xml · nonDerivative · entry 4 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 400 | $39.33 | $15,732.00 |
DisclosureSEC source: 0001209191-20-040660 · doc4.xml · nonDerivative · entry 3 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 500 | $38.78 | $19,392.00 |
DisclosureSEC source: 0001209191-20-040660 · doc4.xml · nonDerivative · entry 2 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,177 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price and includes 200 shares sold at $38.19 and 300 shares sold at $39.18. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,100 | $37.72 | $343,274.75 |
DisclosureSEC source: 0001209191-20-040660 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,677 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.16 to $38.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 30,000 | $50.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-20-039103 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-20-038511 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 01:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,714 | $35.38 | $237,572.88 |
DisclosureSEC source: 0001209191-20-033779 · doc4.xml · nonDerivative · entry 2 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 01:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,286 | $34.53 | $113,465.25 |
DisclosureSEC source: 0001209191-20-033779 · doc4.xml · nonDerivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,491 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 00:56 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $21.73 | $0.00 |
DisclosureSEC source: 0001209191-20-013608 · doc4.xml · derivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 25, 2021, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 111,111 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053065 · doc4.xml · derivative · entry 1 Horn Howard · CIK 0001786335 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,111 Underlying: Common Stock · 111,111 shares Expires 2029-10-10 F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on October 10, 2020, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.